Drug Trial Radar · NCT05126303
Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
177
Actual
Start
Mar 31, 2022
Primary completion
Apr 15, 2023
Study completion Jul 12, 2023
Sponsor
- Lead sponsor
- Guard Therapeutics ABIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates RMC-035 compared to placebo for the prevention of acute kidney injury (AKI) in subjects who are at high risk for AKI following cardiac surgery. Half of the subjects will receive RMC-035 and the other half will receive placebo.
Conditions
- Acute Kidney Injury
Interventions
RMC-035Drug
Concentrate for Solution for Infusion
PlaceboDrug
Concentrate for Solution for Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Developing AKI, as Defined Per Kidney Disease Improving Global Outcomes (KDIGO) CriteriaTime frame: 72 hours
Locations
29 sites in 5 countries. Site status is shown where the registry gives one.
Indiana Ohio Heart
Fort Wayne, Indiana
Bryan Heart
Lincoln, Nebraska
Rochester Regional Health - Rochester General Hospital
Rochester, New York
Duke University Hospital
Durham, North Carolina
Baylor Scott and White Research Institute - Dallas
Dallas, Texas
University of Virginia (UVA) Health - University Hospital
Charlottesville, Virginia
University of Wisconsin
Madison, Wisconsin
Aurora Health Care - Aurora St. Luke's Medical Center
Milwaukee, Wisconsin
Hamilton Health Sciences
Hamilton, Canada
CHUM
Montreal, Canada
MUHC - Royal Victoria Hospital
Montreal, Canada
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Canada
St. John Regional Hospital
Saint John, Canada
Saint Michael's Hospital
Toronto, Canada
University Hospital Hradec Kralove
Hradec Králové, Czechia
University Hospital Motol - Charles University Prague
Prague, Czechia
Herz- und Diabeteszentrum Nordrhein-Westfalen (NRW)
Bad Oeynhausen, Germany
Universitätsklinikum Köln
Cologne, Germany
Herzzentrum Dresden GmbH
Dresden, Germany
Westdeutsches Herzzentrum Essen
Essen, Germany
Universitätsklinikum Giessen und Marburg - Standort Giessen
Giessen, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Deutsches Herzzentrum München
München, Germany
Münster University Hospital
Münster, Germany
Hospital Sant Pau
Barcelona, Spain
Reina Sofia University Hospital
Córdoba, Spain
Hospital de La Princesa
Madrid, Spain
Hospital Universitario Central de Asturias
Oviedo, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.